Dalton Pharma Services

Activities: Manufacturing Research & Development

Trending Articles

  1. Why CGT manufacturers should automate the production process Cell and gene therapies can be highly complex and time-consuming to produce at scale; full robotic automation could help biologics manufacturers to make processes more space,...
  2. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  3. Leybold launches Duradry vacuum pump for harsh processes Advanced technology designed for reliability and efficiency
  4. Pfizer appoints Chris Boshoff as Chief Scientific Officer and President of R&D Dr Boshoff will be responsible for overseeing and advancing Pfizer's R&D initiatives across all therapeutic areas
  5. Anton Paar expands Litesizer DIA Series with new models Introducing affordable and advanced solutions for particle analysis

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

Related Content

Manufacturing

3P innovation secures multimillion-pound deal with Dalton Pharma Services for advanced robotic powder filling technology

Pharmaceutical manufacturing company, Dalton Pharma Services (DPS, a Seikagaku Group company), has recently commissioned 3P innovation (Warwick, UK) to design and construct a fully automated state-of-the-art high-speed aseptic powder filling line to expedite the delivery of drugs to market in a more compliant, efficient and economical manner
Ingredients

Tetra Bio-Pharma engages Dalton Pharma for GMP manufacturing

Tetra Bio-Pharma has awarded the contract for the manufacturing of its active pharmaceutical ingredient ARDS-003
Manufacturing

Dalton expands sterile fill/finish capabilities

The Toronto-based pharma services company said investment is part of a US$10m facility and capital expansion
Manufacturing

Dalton Pharma Services completes $5 million expansion

The project was supported by CA$2.085 million of funding from FedDev Ontario
Manufacturing

Lonza and Dalton to provide integrated chemistry services

Dalton adds geographic diversification to Lonza facilities network

Dalton's GMP oligonucleotide facility ready to roll

<p>Dalton Pharma Services, a privately-owned Canadian pharmaceutical services provider has completed the commissioning of its new oligonucleotide production suite.</p>
Subscribe now